Of the 553 consecutive patients with de novo AML, CEBPA mutations were detected in 105 patients (18.99%), with 81 cases (14.65%) harboring double mutations and 24 cases (4.34%) harboring single mutations. This evidence concerns the gene CEBPA and acute myeloid leukemia.